Quince Therapeutics, Inc. 8-K/A
Research Summary
AI-generated summary
Quince Therapeutics Replaces Press Release in 8-K (Regulation FD)
What Happened
- Quince Therapeutics, Inc. (QNCX) filed a Form 8‑K on May 18, 2026 (Item 7.01) to furnish a replacement Exhibit 99.2 — a press release issued on May 18, 2026 — that replaces the Exhibit 99.2 furnished with the original filing. The 8‑K also includes the Interactive Data File (Exhibit 104) under Item 9.01.
Key Details
- Filing date: May 18, 2026.
- Item reported: 7.01 (Regulation FD Disclosure) — replacement of Exhibit 99.2 (press release).
- Exhibit listed: 99.2 (Press Release issued May 18, 2026) and 104 (Cover Page Interactive Data File).
Why It Matters
- This 8‑K signals Quince has updated public disclosure by replacing a previously submitted press release. Investors should review the replacement Exhibit 99.2 to see what was corrected or updated. The filing does not report earnings, management changes, mergers, or other financial statements — it documents a regulatory disclosure update under Regulation FD.
Loading document...